CD4 and inflammatory bowel disease: The discovery that a specific subgroup of patients with CD develops altered CD4+ T cell responses and ASCAs against yeasts, whereas other patients with IBD do not, underscores the presence of fundamentally distinct host–microbe interactions within this subgroup of patients.